Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Hodgkin Disease 13Lymphoma 8Lymphoma, Large-Cell, Anaplastic 7Hematologic Diseases 7Lymphoma, Non-Hodgkin 5Recurrence 4Lymphoma, T-Cell, Cutaneous 4Mycosis Fungoides 3Sezary Syndrome 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, T-Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cyclophosphamide 72Cytarabine 46fludarabine phosphate 45fludarabine 42Vincristine 29Filgrastim 27Peripheral Blood Stem Cell Transplantation 25Methotrexate 25Etoposide 24Dexamethasone 23Melphalan 21Rituximab 20Doxorubicin 19Clofarabine 19Tacrolimus 17Mycophenolic Acid 17Dasatinib 16Bortezomib 15Whole-Body Irradiation 14Vorinostat 14pegaspargase 13Cyclosporine 13Calcium Dobesilate 13Busulfan 13Antilymphocyte Serum 12tanespimycin 10Topotecan 10Stem Cell Transplantation 10Specimen Handling 10Sirolimus 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Brentuximab Vedotin × Clear all
NCT01700751 2019-04-16

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

Washington University School of Medicine

Phase 1 Completed
17 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡